Table 3 Serious AEs occurring in ≥1 of patients overall.

From: Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

AE, n (%)

Midostaurin + SOC

(n = 30)

SOC

(n = 30)

Diarrhea

4 (13)

2 (7)

Nausea

1 (3)

3 (10)

Vomiting

1 (3)

3 (10)

Pyrexia

2 (7)

2 (7)

Deep vein thrombosis

1 (3)

2 (7)

Febrile neutropenia

1 (3)

2 (7)

Anemia

2 (7)

1 (3)

Acute kidney injury

0

2 (7)

Abdominal pain

1 (3)

1 (3)

Parainfluenza virus infection

1 (3)

1 (3)

  1. AE adverse event, SOC standard of care.